<DOC>
	<DOCNO>NCT02783976</DOCNO>
	<brief_summary>This study collect evaluate information safety efficacy Sovaldi-based regimen routine clinical practice Mexico . The primary objective study ass rate adverse drug reaction ( ADRs ) , serious adverse event ( SAEs ) , adverse event ( AEs ) lead dose modification , drug discontinuation , withdrawal study adult patient chronic hepatitis C virus ( HCV ) infection treat Sovaldi routine clinical practice .</brief_summary>
	<brief_title>Sovaldi-based Regimens Patients Mexico With Chronic Hepatitis C Virus Infection Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key HCVinfected patient live Mexico Treatment Sovaldibased regimen , per approve prescribing information , determine patient 's treat physician Key Concurrent participation HCV clinical trial ( except trial test investigational medicinal product ) Patients present risk able follow ( eg , patient plan move leave country prior SVR12 visit ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>